Amgen (AMGN) Reports Published Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
